LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that it has entered into a research collaboration with The National Institutes of Health (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program. The collaboration was established to advance Concert’s deuterium-modified praziquantel program as a potential treatment for schistosomiasis, a disease caused by parasitic worms that affects more than 200 million people worldwide. TRND will support the collaborative evaluation of Concert’s deuterated compounds in a series of in vitro and in vivo preclinical studies and potentially through Phase 1 clinical testing. The research program will be directed by a joint Concert-TRND steering committee.
